Oral Nutritional Supplements Compared With Standard Diet in Postoperative Gastric Cancer Patients With Adjuvant Chemotherapy
Primary Purpose
Gastric Cancer
Status
Unknown status
Phase
Phase 3
Locations
China
Study Type
Interventional
Intervention
NutrenOpimum
Sponsored by
About this trial
This is an interventional treatment trial for Gastric Cancer focused on measuring gastric cancer, chemothrapy, oral nutritional supplements, malnutrition
Eligibility Criteria
Inclusion Criteria:
- be proven to be primary adenocarcinoma of gastric cancer and pathological confirmed stage II-III or T1N1M0
- age: 18-75 years
- Eastern Cooperative Oncology Group performance status: 0~2
- body mass index: 18.5-28.0kg/m2
- able to ingest semiliquid diet
- without other malignancies with exception of the cured cervical carcinoma in situ and basal cell carcinoma
- anticipated overall survival time ≥ 6 months
- anticipated period of adjuvant chemotherapy ≥ 3
- without severe mental disorder
- without severe digestive disease
- without Acquired Immune Deficiency Syndrome or diabetes mellitus
- without communication barrier
- informed consensus of patients
Exclusion Criteria:
- with unstable hemodynamics
- with severe nausea or vomit which cannot be controlled by drugs
- allergic reaction to NutrenOpimum
- dysfunction of other organs
- with severe disease, such as infection, stroke, heart failure or stock
- other situation to be judged not adaptive to the study by investigators
Sites / Locations
- SunYat-sen University Cancer CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
oral nutritional supplements
standard diet
Arm Description
NutrenOpimum administration was recommended with a dosage of 400 kcal/400 ml per day within 7 days postoperatively and was continued for 3 months postoperatively.
The control group was given no additional postoperative nutritional supplementation (standard diet).
Outcomes
Primary Outcome Measures
postoperative malnutrition
the weight loss at 3 months postoperatively to the days 7 postoperatively body weight (body weight loss ratio) higher than 10%
body weight loss ratio at 1, 3, 6 months
the ratio of the weight loss at 1,3,6 months postoperatively to the days 7 postoperatively body weight
Secondary Outcome Measures
chemotherapy withdrawal
chemotherapy withdrawal by the adverse events or recurrence
time to adjuvant chemotherapy failure
Time to adjuvant treatment chemotherapy failure (TTF) were calculated using the Kaplan-Meier method and compared by the log-rank test
period of adjuvant chemotherapy
period of adjuvant chemotherapy
quality of life
quality of life at 1,3 and 6 months as evaluated by EORTC QLQ-C30
grade 3/4 neutropenia, thrombocytopenia, anemia
grade 3/4 neutropenia, thrombocytopenia, anemia during adjuvant chemotherapy
severe side effects on digestive tract
severe side effects on digestive tract during adjuvant chemotherapy
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03654534
Brief Title
Oral Nutritional Supplements Compared With Standard Diet in Postoperative Gastric Cancer Patients With Adjuvant Chemotherapy
Official Title
Oral Nutritional Supplements Compared With Standard Diet in Postoperative Gastric Cancer Patients With Adjuvant Chemotherapy: a Multicenter, Open-label, Phase 3 Randomised Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
April 2019
Overall Recruitment Status
Unknown status
Study Start Date
April 16, 2019 (Actual)
Primary Completion Date
September 16, 2020 (Anticipated)
Study Completion Date
June 15, 2021 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Sun Yat-sen University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Background: It is known that postoperative malnutrition remains inevitable for gastric cancer patients with adjuvant chemotherapy, which could have prejudicial influence on the compliance of subsequent adjuvant chemotherapy and survival of the patients. A multi-institutional prospective phase 2 study had demonstrated the efficacy of oral nutritional supplements (ONS) for gastric cancer patients undergoing gastrectomy. However, previous studies did not focus the gastric cancer patients with adjuvant chemotherapy. Thus, it is unknown whether the ONS could benefit the gastric cancer patients with adjuvant chemotherapy. A multicenter, phase 3 randomised controlled trial was conducted to compare the ONS with standard diet for postoperative gastric cancer patients with adjuvant chemotherapy. Patients and method: In this study, pathological confirmed stage II-III or T1N1M0 gastric cancer patients who are supposed to receive adjuvant chemotherapy, aged from 18 to 75 years, with body mass index (BMI) from 18.5 to 28.0 kg/m2, and with Eastern Cooperative Oncology Group performance status ≤2, are randomized 1:1 to receive oral administration of NutrenOpimum (Nestle Suisse S.A.), a liquid enteral nutritional food for special medical purpose (FSMP), or standard diet. NutrenOpimum administration was recommended with a dosage of 400 kcal/400 ml per day within 7 days postoperatively and was continued for 3 months postoperatively. The primary end point was postoperative malnutrition, as defined as ratio of the weight loss at 3 months postoperatively to the days 7 postoperatively body weight (body weight loss ratio) higher than 10%; body weight loss ratio at 1, 3, 6 months. Secondary end points were chemotherapy withdrawal, time to adjuvant chemotherapy failure, period of adjuvant chemotherapy, quality of life, grade 3/4 neutropenia, thrombocytopenia, anemia, and severe side effects on digestive tract. Final study analysis will be conducted after the last patient's enrollment.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastric Cancer
Keywords
gastric cancer, chemothrapy, oral nutritional supplements, malnutrition
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
374 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
oral nutritional supplements
Arm Type
Experimental
Arm Description
NutrenOpimum administration was recommended with a dosage of 400 kcal/400 ml per day within 7 days postoperatively and was continued for 3 months postoperatively.
Arm Title
standard diet
Arm Type
No Intervention
Arm Description
The control group was given no additional postoperative nutritional supplementation (standard diet).
Intervention Type
Dietary Supplement
Intervention Name(s)
NutrenOpimum
Intervention Description
NutrenOpimum administration was recommended with a dosage of 400 kcal/400 ml per day within 7 days postoperatively and was continued for 3 months postoperatively.
Primary Outcome Measure Information:
Title
postoperative malnutrition
Description
the weight loss at 3 months postoperatively to the days 7 postoperatively body weight (body weight loss ratio) higher than 10%
Time Frame
3 months postoperatively
Title
body weight loss ratio at 1, 3, 6 months
Description
the ratio of the weight loss at 1,3,6 months postoperatively to the days 7 postoperatively body weight
Time Frame
1,3,6 months postoperatively
Secondary Outcome Measure Information:
Title
chemotherapy withdrawal
Description
chemotherapy withdrawal by the adverse events or recurrence
Time Frame
6 months
Title
time to adjuvant chemotherapy failure
Description
Time to adjuvant treatment chemotherapy failure (TTF) were calculated using the Kaplan-Meier method and compared by the log-rank test
Time Frame
6 months
Title
period of adjuvant chemotherapy
Description
period of adjuvant chemotherapy
Time Frame
6 months
Title
quality of life
Description
quality of life at 1,3 and 6 months as evaluated by EORTC QLQ-C30
Time Frame
6 months
Title
grade 3/4 neutropenia, thrombocytopenia, anemia
Description
grade 3/4 neutropenia, thrombocytopenia, anemia during adjuvant chemotherapy
Time Frame
6 months
Title
severe side effects on digestive tract
Description
severe side effects on digestive tract during adjuvant chemotherapy
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
be proven to be primary adenocarcinoma of gastric cancer and pathological confirmed stage II-III or T1N1M0
age: 18-75 years
Eastern Cooperative Oncology Group performance status: 0~2
body mass index: 18.5-28.0kg/m2
able to ingest semiliquid diet
without other malignancies with exception of the cured cervical carcinoma in situ and basal cell carcinoma
anticipated overall survival time ≥ 6 months
anticipated period of adjuvant chemotherapy ≥ 3
without severe mental disorder
without severe digestive disease
without Acquired Immune Deficiency Syndrome or diabetes mellitus
without communication barrier
informed consensus of patients
Exclusion Criteria:
with unstable hemodynamics
with severe nausea or vomit which cannot be controlled by drugs
allergic reaction to NutrenOpimum
dysfunction of other organs
with severe disease, such as infection, stroke, heart failure or stock
other situation to be judged not adaptive to the study by investigators
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Zhiwei Zhou, Ph.D.
Phone
86(020)87343626
Email
zhouzhw@sysucc.org.cn
First Name & Middle Initial & Last Name or Official Title & Degree
Runcong Nie, Ph.D.
Phone
86-15626447119
Email
nierc@sysucc.org.cn
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Zhiwei Zhou, Ph.D.
Organizational Affiliation
SunYat-sen University
Official's Role
Study Chair
Facility Information:
Facility Name
SunYat-sen University Cancer Center
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510060
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhiwei Zhou, Ph.D.
Phone
86-1390222289
Email
zhouzhw@sysucc.org.cn
First Name & Middle Initial & Last Name & Degree
Runcong Nie, Ph.D.
Phone
86-15626447119
Email
nierc@sysucc.org.cn
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Oral Nutritional Supplements Compared With Standard Diet in Postoperative Gastric Cancer Patients With Adjuvant Chemotherapy
We'll reach out to this number within 24 hrs